Be part of the knowledge.™

Innovative Atherosclerosis Treatments

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
The Society for Heart Attack Prevention and Eradication, SHAPE is focused on several primary interventions to eliminate heart attacks. Join Dr. Larry Kaskel interviewing Dr. Morteza Naghavi and Dr. P.K. Shah to learn about several of SHAPES' top priorities including the polypill and the vaccination for atherosclerosis. What is a polypill and does it make sense? Also, where are we in the current prospect of a vaccine for atherosclerosis?

Morteza Naghavi, MD

Morteza Naghavi, MD

Larry Kaskel, MD

Larry Kaskel, MD

Prediman Shah, MD

Prediman Shah, MD

Recommended

Details

Presenters

Overview
The Society for Heart Attack Prevention and Eradication, SHAPE is focused on several primary interventions to eliminate heart attacks. Join Dr. Larry Kaskel interviewing Dr. Morteza Naghavi and Dr. P.K. Shah to learn about several of SHAPES' top priorities including the polypill and the vaccination for atherosclerosis. What is a polypill and does it make sense? Also, where are we in the current prospect of a vaccine for atherosclerosis?

Morteza Naghavi, MD

Morteza Naghavi, MD

Larry Kaskel, MD

Larry Kaskel, MD

Prediman Shah, MD

Prediman Shah, MD

Program Chapters

Segment Chapters

Playlist:

Recommended

Phase 3 study results of plozasiran in patients with FCS

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

$IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement$

IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement

Biomarkers of the Storm: Decoding IRI’s Signature

Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy

Navigating Myasthenia Gravis in Adolescents and Young Adults

Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids

Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial